VeriMomrh-oligopeptide-1 est-il sûr pendant la grossesse ?
No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
Pregnancy-safe products containing rh-oligopeptide-1
Related ingredients
Frequently asked questions
- rh-oligopeptide-1 est-il sûr pendant la grossesse ?
- No harmonised CLP classification (ECHA Annex VI) or SCCS/CIR reproductive safety restriction identified. However, as a peptide growth factor (EGF family) there is a theoretical class-based concern about mitogenic activity relevant to developing tissues; no animal or human reproductive toxicity data were identified to confirm hazard (sources searched: ECHA Annex VI, SCCS/CIR, PubMed, PubChem/CosIng, EWG). Topical systemic absorption for large peptides like rhEGF is expected to be negligible, so direct systemic exposure in pregnancy is unlikely.
- rh-oligopeptide-1 est-il sûr pendant l'allaitement ?
- Same rationale as pregnancy: theoretical concern from growth-factor activity if systemically absorbed, but no evidence of reproductive or lactation-specific toxicity or breast milk transfer. Large peptide size and available topical formulations suggest negligible systemic bioavailability after topical cosmetic use (sources: PubMed, PubChem, CosIng, EWG).
- rh-oligopeptide-1 est-il sûr pour la peau de bébé ?
- Hazard and mechanism scores unchanged (no infant-specific data showing reproductive/ developmental toxicity). Exposure score increased by +1 because infant skin has a less mature barrier and higher surface-area-to-weight ratio; if the peptide has any measurable percutaneous uptake the relative exposure in 0–3 yr olds would be higher. No studies demonstrating placental/breastmilk transfer or infant adverse outcomes were found (sources: PubMed, CosIng, PubChem, EWG).
- Comment VeriMom évalue-t-il rh-oligopeptide-1 ?
- VeriMom évalue rh-oligopeptide-1 à 73/100 (risque faible) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à rh-oligopeptide-1 pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à rh-oligopeptide-1 basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.